<!DOCTYPE article
PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD with MathML3 v1.2 20190208//EN" "JATS-archivearticle1-mathml3.dtd">
<article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" article-type="research-article"><?properties open_access?><front><journal-meta><journal-id journal-id-type="nlm-ta">Pediatr Rheumatol Online J</journal-id><journal-id journal-id-type="iso-abbrev">Pediatr Rheumatol Online J</journal-id><journal-title-group><journal-title>Pediatric Rheumatology Online Journal</journal-title></journal-title-group><issn pub-type="epub">1546-0096</issn><publisher><publisher-name>BioMed Central</publisher-name><publisher-loc>London</publisher-loc></publisher></journal-meta><article-meta><article-id pub-id-type="pmid">31924225</article-id><article-id pub-id-type="pmc">6954608</article-id><article-id pub-id-type="publisher-id">399</article-id><article-id pub-id-type="doi">10.1186/s12969-020-0399-1</article-id><article-categories><subj-group subj-group-type="heading"><subject>Research Article</subject></subj-group></article-categories><title-group><article-title>Tocilizumab modifies clinical and laboratory features of macrophage activation syndrome complicating systemic juvenile idiopathic arthritis</article-title></title-group><contrib-group><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid">http://orcid.org/0000-0003-1077-7772</contrib-id><name><surname>Shimizu</surname><given-names>Masaki</given-names></name><address><email>shimizum@staff.kanazawa-u.ac.jp</email></address><xref ref-type="aff" rid="Aff1">1</xref></contrib><contrib contrib-type="author"><name><surname>Mizuta</surname><given-names>Mao</given-names></name><xref ref-type="aff" rid="Aff1">1</xref></contrib><contrib contrib-type="author"><name><surname>Okamoto</surname><given-names>Nami</given-names></name><xref ref-type="aff" rid="Aff2">2</xref></contrib><contrib contrib-type="author"><name><surname>Yasumi</surname><given-names>Takahiro</given-names></name><xref ref-type="aff" rid="Aff3">3</xref></contrib><contrib contrib-type="author"><name><surname>Iwata</surname><given-names>Naomi</given-names></name><xref ref-type="aff" rid="Aff4">4</xref></contrib><contrib contrib-type="author"><name><surname>Umebayashi</surname><given-names>Hiroaki</given-names></name><xref ref-type="aff" rid="Aff5">5</xref></contrib><contrib contrib-type="author"><name><surname>Okura</surname><given-names>Yuka</given-names></name><xref ref-type="aff" rid="Aff6">6</xref></contrib><contrib contrib-type="author"><name><surname>Kinjo</surname><given-names>Noriko</given-names></name><xref ref-type="aff" rid="Aff7">7</xref></contrib><contrib contrib-type="author"><name><surname>Kubota</surname><given-names>Tomohiro</given-names></name><xref ref-type="aff" rid="Aff8">8</xref></contrib><contrib contrib-type="author"><name><surname>Nakagishi</surname><given-names>Yasuo</given-names></name><xref ref-type="aff" rid="Aff9">9</xref></contrib><contrib contrib-type="author"><name><surname>Nishimura</surname><given-names>Kenichi</given-names></name><xref ref-type="aff" rid="Aff10">10</xref></contrib><contrib contrib-type="author"><name><surname>Mohri</surname><given-names>Mariko</given-names></name><xref ref-type="aff" rid="Aff11">11</xref></contrib><contrib contrib-type="author"><name><surname>Yashiro</surname><given-names>Masato</given-names></name><xref ref-type="aff" rid="Aff12">12</xref></contrib><contrib contrib-type="author"><name><surname>Yasumura</surname><given-names>Junko</given-names></name><xref ref-type="aff" rid="Aff13">13</xref></contrib><contrib contrib-type="author"><name><surname>Wakiguchi</surname><given-names>Hiroyuki</given-names></name><xref ref-type="aff" rid="Aff14">14</xref></contrib><contrib contrib-type="author"><name><surname>Mori</surname><given-names>Masaaki</given-names></name><xref ref-type="aff" rid="Aff11">11</xref></contrib><aff id="Aff1"><label>1</label><institution-wrap><institution-id institution-id-type="ISNI">0000 0001 2308 3329</institution-id><institution-id institution-id-type="GRID">grid.9707.9</institution-id><institution>Department of Pediatrics, Graduate School of Medical Sciences, </institution><institution>Kanazawa University, </institution></institution-wrap>13-1 Takaramachi, Kanazawa, 920-8641 Japan </aff><aff id="Aff2"><label>2</label><institution-wrap><institution-id institution-id-type="ISNI">0000 0001 2109 9431</institution-id><institution-id institution-id-type="GRID">grid.444883.7</institution-id><institution>Department of Pediatrics, Osaka Medical College, </institution></institution-wrap>Takatsuki, Japan </aff><aff id="Aff3"><label>3</label><institution-wrap><institution-id institution-id-type="ISNI">0000 0004 0372 2033</institution-id><institution-id institution-id-type="GRID">grid.258799.8</institution-id><institution>Department of Pediatrics, </institution><institution>Kyoto University Graduate School of Medicine, </institution></institution-wrap>Kyoto, Japan </aff><aff id="Aff4"><label>4</label>Department of Immunology and Infectious Diseases, Aichi Children&#x02019;s Health and Medical Center, Obu, Japan </aff><aff id="Aff5"><label>5</label><institution-wrap><institution-id institution-id-type="ISNI">0000 0004 0471 4457</institution-id><institution-id institution-id-type="GRID">grid.415988.9</institution-id><institution>Department of Rheumatics, </institution><institution>Miyagi Children&#x02019;s Hospital, </institution></institution-wrap>Sendai, Japan </aff><aff id="Aff6"><label>6</label><institution-wrap><institution-id institution-id-type="ISNI">0000 0004 1771 5774</institution-id><institution-id institution-id-type="GRID">grid.417164.1</institution-id><institution>Department of Pediatrics, </institution><institution>KKR Sapporo Medical Center, </institution></institution-wrap>Sapporo, Japan </aff><aff id="Aff7"><label>7</label><institution-wrap><institution-id institution-id-type="ISNI">0000 0001 0685 5104</institution-id><institution-id institution-id-type="GRID">grid.267625.2</institution-id><institution>Department of Pediatrics, Faculty of Medicine, </institution><institution>University of the Ryukyus, </institution></institution-wrap>Nakagami-gun, Japan </aff><aff id="Aff8"><label>8</label><institution-wrap><institution-id institution-id-type="ISNI">0000 0001 1167 1801</institution-id><institution-id institution-id-type="GRID">grid.258333.c</institution-id><institution>Department of Pediatrics, Graduate School of Medical and Dental Sciences, </institution><institution>Kagoshima University, </institution></institution-wrap>Kagoshima, Japan </aff><aff id="Aff9"><label>9</label><institution-wrap><institution-id institution-id-type="GRID">grid.415413.6</institution-id><institution>Department of Pediatric Rheumatology, </institution><institution>Hyogo Prefectural Kobe Children&#x02019;s Hospital, </institution></institution-wrap>Kobe, Japan </aff><aff id="Aff10"><label>10</label><institution-wrap><institution-id institution-id-type="ISNI">0000 0001 1033 6139</institution-id><institution-id institution-id-type="GRID">grid.268441.d</institution-id><institution>Department of Pediatrics, </institution><institution>Yokohama City University Graduate School of Medicine, </institution></institution-wrap>Yokohama, Japan </aff><aff id="Aff11"><label>11</label><institution-wrap><institution-id institution-id-type="ISNI">0000 0001 1014 9130</institution-id><institution-id institution-id-type="GRID">grid.265073.5</institution-id><institution>Department of Lifetime Clinical Immunology, Graduate School of Medical and Dental Sciences, </institution><institution>Tokyo Medical and Dental University, </institution></institution-wrap>Tokyo, Japan </aff><aff id="Aff12"><label>12</label><institution-wrap><institution-id institution-id-type="ISNI">0000 0004 0631 9477</institution-id><institution-id institution-id-type="GRID">grid.412342.2</institution-id><institution>Department of Pediatrics, </institution><institution>Okayama University Hospital, </institution></institution-wrap>Okayama, Japan </aff><aff id="Aff13"><label>13</label><institution-wrap><institution-id institution-id-type="ISNI">0000 0000 8711 3200</institution-id><institution-id institution-id-type="GRID">grid.257022.0</institution-id><institution>Department of Pediatrics, </institution><institution>Hiroshima University Graduate School of Biomedical &#x00026; Health Sciences, </institution></institution-wrap>Hiroshima, Japan </aff><aff id="Aff14"><label>14</label><institution-wrap><institution-id institution-id-type="ISNI">0000 0001 0660 7960</institution-id><institution-id institution-id-type="GRID">grid.268397.1</institution-id><institution>Department of Pediatrics, </institution><institution>Yamaguchi University Graduate School of Medicine, </institution></institution-wrap>Ube, Japan </aff></contrib-group><pub-date pub-type="epub"><day>10</day><month>1</month><year>2020</year></pub-date><pub-date pub-type="pmc-release"><day>10</day><month>1</month><year>2020</year></pub-date><pub-date pub-type="collection"><year>2020</year></pub-date><volume>18</volume><elocation-id>2</elocation-id><history><date date-type="received"><day>12</day><month>9</month><year>2019</year></date><date date-type="accepted"><day>6</day><month>1</month><year>2020</year></date></history><permissions><copyright-statement>&#x000a9; The Author(s). 2020</copyright-statement><license license-type="OpenAccess"><license-p><bold>Open Access</bold>This article is distributed under the terms of the Creative Commons Attribution 4.0 International License (<ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/licenses/by/4.0/">http://creativecommons.org/licenses/by/4.0/</ext-link>), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (<ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/publicdomain/zero/1.0/">http://creativecommons.org/publicdomain/zero/1.0/</ext-link>) applies to the data made available in this article, unless otherwise stated.</license-p></license></permissions><abstract id="Abs1"><sec><title>Background</title><p id="Par1">This study aimed to determine the influence of tocilizumab (TCZ) in modifying the clinical and laboratory features of macrophage activation syndrome (MAS) complicating systemic juvenile idiopathic arthritis (s-JIA). Furthermore, we assessed the performance of the 2016 MAS classification criteria for patients with s-JIA-associated MAS while treated with TCZ.</p></sec><sec><title>Methods</title><p id="Par2">A panel of 15 pediatric rheumatologists conducted a combination of expert consensus and analysis of real patient data. Clinical and laboratory features of s-JIA-associated MAS in 12 TCZ-treated patients and 18 untreated patients were evaluated. Possible MAS was defined as having characteristic laboratory features but lack of clinical features of MAS, or atypical MAS, or early treatment that prevented full-blown MAS.</p></sec><sec><title>Results</title><p id="Par3">Clinically, the TCZ-treated patients with s-JIA-associated MAS were less likely febrile and had significantly lower ferritin, triglyceride, and CRP levels than the untreated patients with s-JIA-associated MAS. Other laboratory features of MAS including lower platelet counts and lower fibrinogen were more pronounced in TCZ-treated patients. The TCZ-treated patients with s-JIA-associated MAS were less likely to be classified as MAS based on the MAS classification criteria (25% vs 83.3%, <italic>p</italic>&#x000a0;&#x0003c;&#x02009;0.01). This is ascribed to the absence of fever or insufficient ferritin elevation, compared with the untreated patients.</p></sec><sec><title>Conclusion</title><p id="Par4">TCZ could modify the clinical and laboratory features of s-JIA-associated MAS. When evaluating the s-JIA patients while treated with TCZ, it is not applicable to use MAS classification criteria. Care must be taken to not underdiagnose MAS based on the MAS classification criteria.</p></sec></abstract><kwd-group xml:lang="en"><title>Keywords</title><kwd>Macrophage activation syndrome</kwd><kwd>Systemic juvenile idiopathic arthritis</kwd><kwd>Tocilizumab</kwd><kwd>Classification criteria</kwd></kwd-group><funding-group><award-group><funding-source><institution>Research on rare and intractable diseases, Health and Labour Sciences Research Grants</institution></funding-source></award-group></funding-group><custom-meta-group><custom-meta><meta-name>issue-copyright-statement</meta-name><meta-value>&#x000a9; The Author(s) 2020</meta-value></custom-meta></custom-meta-group></article-meta></front><body><sec id="Sec1"><title>Background</title><p id="Par12">Macrophage activation syndrome (MAS) is a severe, potentially life-threatening complication of rheumatic diseases, which is clinically characterized by fever, hepatosplenomegaly, lymphadenopathy, profound depression of all three blood cell lines, deranged liver function, intravascular coagulation, and central nervous system dysfunction. The hallmark of MAS is an uncontrolled and dysfunctional immune response with excessive activation and expansion of T lymphocytes and macrophages exhibiting hemophagocytic activity, which leads to overproduction of numerous proinflammatory mediators, thereby eliciting a cytokine storm. MAS is complicated with many rheumatic diseases. However, MAS is most commonly seen in systemic juvenile idiopathic arthritis (s-JIA) and occurs in approximately 10% patients with s-JIA [<xref ref-type="bibr" rid="CR1">1</xref>]. Furthermore, subclinical or occult MAS may occur in as many as 30&#x02013;40% patients with active s-JIA [<xref ref-type="bibr" rid="CR2">2</xref>].</p><p id="Par13">s-JIA is a severe systemic inflammatory disorder of unknown etiology characterized by arthritis and systemic features such as spiking fever, skin rash, generalized lymphadenopathy, hepatosplenomegaly, and serositis. Although the pathophysiology of s-JIA remains obscure, it has been suggested that s-JIA is an auto-inflammatory condition driven by continuous activation of innate immune pathways, leading to aberrant induction of proinflammatory cytokines, such as interleukin (IL)-6, IL-1&#x003b2;, and IL-18 [<xref ref-type="bibr" rid="CR1">1</xref>].</p><p id="Par14">Tocilizumab (TCZ), a humanized anti-IL-6 receptor monoclonal antibody, serves as a clinically effective cytokine inhibitor for the treatment of s-JIA. Despite high efficacy for the treatment of s-JIA, recent studies have revealed that MAS could be complicated in patients with s-JIA receiving TCZ therapy [<xref ref-type="bibr" rid="CR3">3</xref>, <xref ref-type="bibr" rid="CR4">4</xref>]. Furthermore, TCZ has been reported to modify and mask the clinical symptoms and laboratory findings of MAS in patients with s-JIA [<xref ref-type="bibr" rid="CR3">3</xref>, <xref ref-type="bibr" rid="CR4">4</xref>].</p><p id="Par15">On that account, prompt and rapid diagnosis is essential to initiate appropriate treatment for s-JIA-associated MAS. However, it is often difficult and challenging to distinguish s-JIA-associated MAS from s-JIA flares. The classification criteria for MAS in the setting of s-JIA based on expert consensus along with a large patient databank was reported in 2016 [<xref ref-type="bibr" rid="CR5">5</xref>]. We previously validated these criteria and showed these criteria had a very high performance for the diagnosis of full-blown MAS with high sensitivity and specificity in the real world [<xref ref-type="bibr" rid="CR6">6</xref>]. However, a recent systematic literature review revealed that the clinical and laboratory features of s-JIA-associated MAS could be modified in patients treated with biologic agents including TCZ [<xref ref-type="bibr" rid="CR4">4</xref>].</p><p id="Par16">Therefore, this study aimed to determine the influence of TCZ in modifying the clinical and laboratory features of s-JIA-associated MAS and to assess performance of the 2016 MAS classification criteria for patients with s-JIA-associated MAS while treated with TCZ in the real world.</p></sec><sec id="Sec2"><title>Methods</title><p id="Par17">This is a multicenter, retrospective, case-control study including TCZ-treated and TCZ-untreated s-JIA patients with MAS. For patients with MAS, information on the laboratory features from acute s-JIA phase to MAS phase that included at least three time points (the last visit before MAS onset, the time of MAS onset, and the period of full-blown MAS) were collected. MAS onset was defined as the time when the initial clinical and/or laboratory abnormalities suggesting the occurrence of MAS were detected. Full-blown MAS was defined as the time at which MAS reached its most severe stage. Possible MAS was defined as the condition when patients had characteristic laboratory features but lack of clinical features of MAS or when early treatment prevented full-blown MAS [<xref ref-type="bibr" rid="CR7">7</xref>, <xref ref-type="bibr" rid="CR8">8</xref>].</p><p id="Par18">We enrolled 36 Japanese MAS patients treated with TCZ from 2006 to 2017. Investigators were asked to include s-JIA patients with MAS seen after 2006. This timeframe was chosen because preliminary diagnostic guidelines for the diagnosis of MAS was reported in 2005 [<xref ref-type="bibr" rid="CR9">9</xref>]. We reported 36 patients from 14 institutes of pediatric rheumatology in Japan. A panel of 15 experts was first asked to diagnose the 36 patient profiles with or without MAS based on clinical and laboratory features at the time of disease onset. A combination of expert consensus and analysis of real patient data was conducted by a panel of 15 pediatric rheumatologists. The minimum required level of agreement among experts was set at 80%. Of the 36 patient profiles, 20 were excluded because of insufficient data. At the 36 patient data points for MAS, platelet counts and serum AST levels were measured in all 36 patient data points. On the other hand, serum ferritin levels were measured in 33 patient data points (91.6%), TG was measured in 23 patient data points (63.8%) and fibrinogen in 26 patient data points (72.2%). Among the remaining 16 patient profiles measured all items that fulfilled the MAS criteria, 12 were diagnosed with MAS and four without MAS by the experts. We also re-evaluated real patient data from 18 MAS patients not treated with TCZ in our previous historic cohort [<xref ref-type="bibr" rid="CR6">6</xref>]. Clinical and laboratory features of s-JIA-associated MAS upon MAS diagnosis were evaluated, and the data was compared between the TCZ-treated and TCZ-untreated MAS patient groups. Table&#x000a0;<xref rid="Tab1" ref-type="table">1</xref> shows the clinical characteristics of patient data at the time of MAS diagnosis.
<table-wrap id="Tab1"><label>Table 1</label><caption><p>Demographic and clinical features of patients with macrophage activation syndrome</p></caption><table frame="hsides" rules="groups"><thead><tr><th/><th colspan="3">Tocilizumab</th><th colspan="3">Historic cohort</th></tr><tr><th/><th>Full-blown</th><th>Possible</th><th>All</th><th>Full-blown</th><th>Possible</th><th>All</th></tr></thead><tbody><tr><td>Number</td><td>2</td><td>10</td><td>12</td><td>10</td><td>8</td><td>18</td></tr><tr><td colspan="7">Sex, no.</td></tr><tr><td>&#x02003;Female</td><td>1</td><td>7</td><td>8</td><td>3</td><td>5</td><td>8</td></tr><tr><td>&#x02003;Male</td><td>1</td><td>3</td><td>4</td><td>7</td><td>3</td><td>10</td></tr><tr><td>&#x02003;Age, median (IQR)</td><td>6 (3&#x02013;9)</td><td>8.5 (7&#x02013;14.75)</td><td>8.5 (7&#x02013;12.75)</td><td>5 (1.75&#x02013;6.75)</td><td>8 (3.5&#x02013;9.5)</td><td>5.5 (2&#x02013;8.25)</td></tr><tr><td>&#x02003;Fever (%, n)</td><td>50 (1/2)</td><td>50 (5/10)*</td><td>50 (6/12)**</td><td>90 (9/10)</td><td>100 (8/8)*</td><td>94.4 (17/18)**</td></tr><tr><td>&#x02003;Hepatosplenomegaly (%, n)</td><td>0 (0/2)</td><td>30 (3/10)</td><td>25 (3/12)</td><td>40 (4/10)</td><td>37.5 (3/8)</td><td>38.9 (7/18)</td></tr><tr><td>&#x02003;Lymphadenopathy (%, n)</td><td>0 (0/2)</td><td>20 (2/10)</td><td>16.7 (2/12)</td><td>30 (3/10)</td><td>37.5 (3/8)</td><td>33.3 (6/18)</td></tr><tr><td>&#x02003;CNS (%, n)</td><td>0 (0/2)</td><td>0 (0/10)</td><td>0 (0/12)</td><td>0 (0/10)</td><td>0 (0/8)</td><td>0 (0/18)</td></tr></tbody></table><table-wrap-foot><p><italic>CNS</italic> Central nervous system, *&#x02009;=&#x000a0;<italic>p</italic>&#x000a0;&#x0003c;&#x02009;0.05; **&#x02009;=&#x000a0;<italic>p</italic>&#x000a0;&#x0003c;&#x02009;0.01;</p></table-wrap-foot></table-wrap></p><sec id="Sec3"><title>Statistical analysis</title><p id="Par19">Within-group comparison was analyzed using Mann&#x02013;Whitney test or Fisher&#x02019;s exact test. <italic>P</italic>&#x000a0;&#x0003c;&#x02009;0.05 was considered statistically significant.</p></sec></sec><sec id="Sec4"><title>Results</title><sec id="Sec5"><title>TCZ modifies the clinical and laboratory features of s-JIA-associated MAS</title><p id="Par20">Among the 12 TCZ-treated patients, only two were diagnosed with full-blown MAS and the remaining 10 were diagnosed with possible MAS. Conversely, among 18 TCZ-untreated patients, 10 were diagnosed with full-blown MAS and the remaining eight were diagnosed with possible MAS.</p><p id="Par21">Table <xref rid="Tab1" ref-type="table">1</xref> shows the demographic and clinical features of the patients with MAS. In both the TCZ-treated patients and the TCZ-untreated patients, no significant differences with respect to age and sex were observed. The TCZ-treated patients at the time of MAS were significantly less likely to develop fever than the TCZ-untreated patients (Table <xref rid="Tab1" ref-type="table">1</xref>) (possible MAS: <italic>p</italic>&#x000a0;&#x0003c;&#x02009;0.05; MAS All <italic>p</italic>&#x000a0;&#x0003c;&#x02009;0.01). In contrast, no significant differences were noted in other clinical features including hepatosplenomegaly and lymphadenopathy.</p><p id="Par22">Table&#x000a0;<xref rid="Tab2" ref-type="table">2</xref> shows the laboratory findings at the time of MAS diagnosis in patients who developed MAS while treated with TCZ. Although statistical analysis could not be done because of the limited number of patients with full-blown MAS while treated with TCZ, the laboratory findings in patients with full-blown MAS while treated with TCZ seemed to be similarly severe compared with the TCZ-untreated patients (Table <xref rid="Tab2" ref-type="table">2</xref> and Fig.&#x000a0;<xref rid="Fig1" ref-type="fig">1</xref>). In contrast, patients with possible MAS receiving TCZ had significantly lower serum ferritin levels than the TCZ-untreated patients (587&#x02009;ng/ml vs 8518&#x02009;ng/ml; <italic>p</italic>&#x000a0;&#x0003c;&#x02009;0.01) (Table <xref rid="Tab2" ref-type="table">2</xref> and Fig. <xref rid="Fig1" ref-type="fig">1</xref>a). Furthermore, patients with possible MAS receiving TCZ had significantly lower serum triglyceride (TG) levels (108&#x02009;mg/dl vs 148&#x02009;mg/dl; <italic>p</italic>&#x000a0;&#x0003c;&#x02009;0.05) (Table <xref rid="Tab2" ref-type="table">2</xref> and Fig. <xref rid="Fig1" ref-type="fig">1</xref>b) and serum C reactive protein (CRP) levels (0.03&#x02009;mg/dl vs 9.6&#x02009;mg/dl; <italic>p</italic>&#x000a0;&#x0003c;&#x02009;0.0001) than the TCZ-untreated patients (Table <xref rid="Tab2" ref-type="table">2</xref> and Fig. <xref rid="Fig1" ref-type="fig">1</xref>c). All patients with MAS (full-blown + possible MAS) receiving TCZ also had significantly lower serum ferritin levels (664&#x02009;ng/ml vs 9235&#x02009;ng/ml; <italic>p</italic>&#x000a0;&#x0003c;&#x02009;0.001) (Table <xref rid="Tab2" ref-type="table">2</xref> and Fig. <xref rid="Fig1" ref-type="fig">1</xref>a), serum TG levels (113&#x02009;mg/dl vs 214&#x02009;mg/dl; p&#x02009;&#x0003c;&#x02009;0.05) (Table <xref rid="Tab2" ref-type="table">2</xref> and Fig. <xref rid="Fig1" ref-type="fig">1</xref>b), and serum CRP levels (0.03&#x02009;mg/dl vs 7.6&#x02009;mg/dl; <italic>p</italic>&#x000a0;&#x0003c;&#x02009;0.0001) than the TCZ-untreated patients (Table <xref rid="Tab2" ref-type="table">2</xref> and Fig. <xref rid="Fig1" ref-type="fig">1</xref>c). Furthermore, patients with possible MAS receiving TCZ also had significantly lower platelet counts (11.7&#x02009;&#x000d7;&#x02009;10<sup>4</sup>/mm<sup>3</sup> vs 21.9&#x02009;&#x000d7;&#x02009;10<sup>4</sup>/mm<sup>3</sup>; <italic>p</italic>&#x000a0;&#x0003c;&#x02009;0.0001) (Table <xref rid="Tab2" ref-type="table">2</xref> and Fig. <xref rid="Fig1" ref-type="fig">1</xref>d) and lower fibrinogen levels (118&#x02009;mg/dl vs 319&#x02009;mg/dl; p&#x02009;&#x0003c;&#x02009;0.0001) (Table <xref rid="Tab2" ref-type="table">2</xref> and Fig. <xref rid="Fig1" ref-type="fig">1</xref>e) than the TCZ-untreated patients. Patients with possible MAS receiving TCZ also had higher serum aspartic aminotransferase (AST) levels than the TCZ-untreated patients (119&#x02009;IU/l vs 63&#x02009;IU/l), but it was not statistically significant (Table <xref rid="Tab2" ref-type="table">2</xref> and Fig. <xref rid="Fig1" ref-type="fig">1</xref>f). All patients with MAS receiving TCZ also had significantly lower platelet counts (11.7&#x02009;&#x000d7;&#x02009;10<sup>4</sup>/mm<sup>3</sup> vs 18.9&#x02009;&#x000d7;&#x02009;10<sup>4</sup>/mm<sup>3</sup>; <italic>p</italic>&#x000a0;&#x0003c;&#x02009;0.001) (Table <xref rid="Tab2" ref-type="table">2</xref> and Fig. <xref rid="Fig1" ref-type="fig">1</xref>d) and lower fibrinogen levels (118&#x02009;mg/dl vs 294&#x02009;mg/dl; <italic>p</italic>&#x000a0;&#x0003c;&#x02009;0.0001) (Table <xref rid="Tab2" ref-type="table">2</xref> and Fig. <xref rid="Fig1" ref-type="fig">1</xref>e) than the TCZ-untreated patients. All patients with MAS receiving TCZ also had higher serum AST levels than the TCZ-untreated patients (161&#x02009;IU/l vs 89&#x02009;IU/l), but it was not statistically significant (Table <xref rid="Tab2" ref-type="table">2</xref> and Fig. <xref rid="Fig1" ref-type="fig">1</xref>f). Taken together, we found significant differences in the key laboratory parameters associated with MAS in TCZ-treated patients.
<table-wrap id="Tab2"><label>Table 2</label><caption><p>Laboratory findings of patients with macrophage activation syndrome</p></caption><table frame="hsides" rules="groups"><thead><tr><th rowspan="2"/><th colspan="3">Tocilizumab</th><th colspan="3">Historic cohort</th></tr><tr><th>Full-blown (<italic>n</italic>&#x000a0;=&#x02009;2)</th><th>Possible (<italic>n</italic>&#x000a0;=&#x02009;10)</th><th>All (<italic>n</italic>&#x000a0;=&#x02009;12)</th><th>Full-blown (n&#x02009;=&#x02009;10)</th><th>Possible (<italic>n</italic>&#x000a0;=&#x02009;8)</th><th>All (<italic>n</italic>&#x000a0;=&#x02009;18)</th></tr></thead><tbody><tr><td rowspan="2">Ferritin (ng/ml)</td><td>12,645</td><td>587**</td><td>664***</td><td>11,035</td><td>8518**</td><td>9235***</td></tr><tr><td>4155&#x02013;21,135</td><td>402&#x02013;2330</td><td>410&#x02013;3785</td><td>6585&#x02013;32,644</td><td>3390&#x02013;11,833</td><td>5559&#x02013;18,710</td></tr><tr><td rowspan="2">Platelets (&#x000d7;&#x02009;10<sup>4</sup>/mm<sup>3</sup>)</td><td>12.4</td><td>11.7****</td><td>11.7***</td><td>14.5</td><td>21.9****</td><td>18.9***</td></tr><tr><td>7.6&#x02013;17.2</td><td>7.7&#x02013;13.1</td><td>7.7&#x02013;13.3</td><td>12.1&#x02013;18.5</td><td>20.2&#x02013;32.2</td><td>13.3&#x02013;21.8</td></tr><tr><td rowspan="2">AST (IU/l)</td><td>666</td><td>119</td><td>161</td><td>296</td><td>63</td><td>89</td></tr><tr><td>382&#x02013;949</td><td>61&#x02013;290</td><td>63&#x02013;438</td><td>78&#x02013;681</td><td>53&#x02013;92</td><td>61&#x02013;425</td></tr><tr><td rowspan="2">TG (mg/dl)</td><td>362</td><td>108*</td><td>113*</td><td>279</td><td>148*</td><td>214*</td></tr><tr><td>149&#x02013;574</td><td>91&#x02013;132</td><td>94&#x02013;150</td><td>192&#x02013;298</td><td>141&#x02013;213</td><td>143&#x02013;285</td></tr><tr><td rowspan="2">Fibrinogen (mg/dl)</td><td>116</td><td>118****</td><td>118****</td><td>281</td><td>319****</td><td>294****</td></tr><tr><td>80&#x02013;152</td><td>102&#x02013;172</td><td>97&#x02013;163</td><td>217&#x02013;292</td><td>302&#x02013;482</td><td>240&#x02013;362</td></tr><tr><td rowspan="2">CRP (mg/dl)</td><td>3.1</td><td>0.03****</td><td>0.03****</td><td>7.5</td><td>9.6****</td><td>7.6****</td></tr><tr><td>0.0&#x02013;6.1</td><td>0.0&#x02013;0.6</td><td>0.0&#x02013;6.1</td><td>3.3&#x02013;12.9</td><td>4.7&#x02013;15.1</td><td>3.7&#x02013;13.6</td></tr></tbody></table><table-wrap-foot><p>Median values and IQR were shown. *&#x02009;=&#x000a0;<italic>p</italic>&#x000a0;&#x0003c;&#x02009;0.05; **&#x02009;=&#x000a0;<italic>p</italic>&#x000a0;&#x0003c;&#x02009;0.01; ***&#x02009;=&#x000a0;<italic>p</italic>&#x000a0;&#x0003c;&#x02009;0.001; ****&#x02009;=&#x000a0;<italic>p</italic>&#x000a0;&#x0003c;&#x02009;0.0001; <italic>AST</italic> Aspartic aminotransferase, <italic>TG</italic> Triglyceride, <italic>CRP</italic> C reactive protein</p></table-wrap-foot></table-wrap>
<fig id="Fig1"><label>Fig. 1</label><caption><p>Inflammatory markers are modified in patients with systemic juvenile idiopathic arthritis associated macrophage activation syndrome while treated with tocilizumab, compared to the untreated patients</p><p>Plots show <bold>a</bold>) serum ferritin levels, <bold>b</bold>) serum TG levels <bold>c</bold>) serum CRP levels, <bold>d</bold>) platelets count, <bold>e</bold>) plasma fibrinogen levels, and <bold>f</bold>) serum AST levels. Plots show median values. *&#x02009;=&#x000a0;<italic>p</italic>&#x000a0;&#x0003c;&#x02009;0.05; **&#x02009;=&#x000a0;<italic>p</italic>&#x000a0;&#x0003c;&#x02009;0.01; ***&#x02009;=&#x000a0;<italic>p</italic>&#x000a0;&#x0003c;&#x02009;0.001; ****&#x02009;=&#x000a0;<italic>p</italic>&#x000a0;&#x0003c;&#x02009;0.0001.</p></caption><graphic xlink:href="12969_2020_399_Fig1_HTML" id="MO1"/></fig></p></sec><sec id="Sec6"><title>Validation of 2016 ACR/EULAR classification criteria of MAS complicating s-JIA while treated with TCZ upon MAS diagnosis</title><p id="Par23">For patients with full-blown MAS treated with TCZ, these criteria classified as MAS 50% of patient events (1/2) collected in this study that had been clinically diagnosed as MAS (Table&#x000a0;<xref rid="Tab3" ref-type="table">3</xref>). This result compared with the TCZ-untreated patients, of whom 90% (9/10) were classified as MAS based on the derived criteria. For patients with possible MAS treated with TCZ, only 20% (2/10) could be classified as having MAS, lower than the historical cohort (75%, 6/8). For all patients with MAS (definite + possible MAS) treated with TCZ, only 25% (3/12) could be classified as having MAS, which was significantly lower than the TCZ-untreated patients (83.3%, 15/18, <italic>p</italic>&#x000a0;&#x0003c;&#x02009;0.01). TCZ-treated patients failed to fulfill the classification criteria due to an absence of fever or insufficient ferritin elevation (Table <xref rid="Tab3" ref-type="table">3</xref>).
<table-wrap id="Tab3"><label>Table 3</label><caption><p>Application of 2016 MAS classification criteria to patients with MAS treated with tocilizumab</p></caption><table frame="hsides" rules="groups"><thead><tr><th rowspan="2"/><th colspan="3">Tocilizumab</th><th colspan="3">Historic cohort</th></tr><tr><th>Full-blown</th><th>Possible</th><th>All</th><th>Full-blown</th><th>Possible</th><th>All</th></tr></thead><tbody><tr><td>Number with sufficient data</td><td>2</td><td>10</td><td>12</td><td>10</td><td>8</td><td>18</td></tr><tr><td>MAS (%, n)</td><td>50 (1/2)</td><td>20 (2/10)</td><td>25 (3/12)</td><td>90 (9/10)</td><td>75 (6/8)</td><td>83 (15/18)</td></tr><tr><td rowspan="2">Reasons missing (n)</td><td rowspan="2">Afebrile [<xref ref-type="bibr" rid="CR1">1</xref>]</td><td>Afebrile [<xref ref-type="bibr" rid="CR4">4</xref>]</td><td rowspan="2"/><td rowspan="2">Afebrile [<xref ref-type="bibr" rid="CR1">1</xref>]</td><td rowspan="2">Other markers [<xref ref-type="bibr" rid="CR2">2</xref>]</td><td rowspan="2"/></tr><tr><td>Ferritin [<xref ref-type="bibr" rid="CR5">5</xref>]</td></tr></tbody></table><table-wrap-foot><p><italic>MAS</italic> Macrophage activation syndrome</p></table-wrap-foot></table-wrap></p></sec></sec><sec id="Sec7"><title>Discussion</title><p id="Par24">Inflammatory cytokines including IL-1&#x003b2;, IL-6, and IL-18 play pathogenic roles in the disease processes of s-JIA [<xref ref-type="bibr" rid="CR1">1</xref>]. Since the introduction of biologic agents, most notably targeting IL-1 and IL-6, treatment of s-JIA has dramatically developed. IL-6 plays an important role as an inflammatory mediator in the pathogenesis of s-JIA [<xref ref-type="bibr" rid="CR10">10</xref>]. Serum IL-6 levels in patients with s-JIA correlate with the extent and severity of joint involvement, fever patterns, growth retardation, and osteoporosis [<xref ref-type="bibr" rid="CR10">10</xref>]. The clinical use of TCZ had striking and long-lasting effects on s-JIA, even in patients with severe disease that was refractory to other therapies [<xref ref-type="bibr" rid="CR11">11</xref>]. Despite the efficacy of TCZ treatment, patients with s-JIA still have a risk to develop MAS [<xref ref-type="bibr" rid="CR3">3</xref>, <xref ref-type="bibr" rid="CR4">4</xref>, <xref ref-type="bibr" rid="CR7">7</xref>, <xref ref-type="bibr" rid="CR8">8</xref>]. The rates of MAS complications in s-JIA patients while treated with TCZ were 1.8&#x02013;6.4 per 100 patients, which were similar to those reported in the patients not treated with biologic agents [<xref ref-type="bibr" rid="CR7">7</xref>, <xref ref-type="bibr" rid="CR8">8</xref>, <xref ref-type="bibr" rid="CR12">12</xref>].</p><p id="Par25">In this study, we analyzed whether there was any difference in the clinical and laboratory features of MAS in TCZ-treated patients. The data showed that there were significant alterations in the MAS parameters in TCZ-treated patients. In agreement with our previous case series and recent systematic review [<xref ref-type="bibr" rid="CR3">3</xref>, <xref ref-type="bibr" rid="CR4">4</xref>], TCZ-treated patients were less likely to be febrile and had lower ferritin levels, CRP levels, platelet counts, fibrinogen levels, and TG levels than the historical cohort. These findings indicate that patients with MAS while treated with TCZ may have unconventional symptoms.</p><p id="Par26">In this study, TCZ-treated patients were less likely to be febrile and had lower ferritin and CRP levels. IL-6 is a <italic>representative cytokine to</italic> induce the acute-phase response in the pathogenesis of s-JIA [<xref ref-type="bibr" rid="CR10">10</xref>]. Therefore, modification of these clinical manifestations by TCZ might be reasonable. In contrast, interestingly, thrombocytopenia and hypofibrinogenemia became more pronounced with TCZ treatment. The reason for these modifications of laboratory findings is still unknown. One possibility is the suppressive effect by TCZ for the IL-6 mediated biosynthesis of fibrinogen in hepatocytes and IL-6 induced thrombopoiesis through thrombopoietin. Another possibility might be the side effect of TCZ itself. Some previous reports showed that s-JIA TCZ-treated patients developed thrombocytopenia [<xref ref-type="bibr" rid="CR7">7</xref>, <xref ref-type="bibr" rid="CR13">13</xref>]. The other possibility is that TCZ might affect the disease process of s-JIA-associated MAS. Furthermore, TCZ masks the clinical symptoms of MAS including fever and elevation of ferritin and CRP levels. This modification might delay the recognition of MAS.</p><p id="Par27">In this study, we validated the classification criteria for MAS in patients with MAS while treated with TCZ and found that the MAS classification criteria were less likely to classify the patients diagnosed with MAS while treated with TCZ due to an absence of fever or insufficient ferritin elevation, compared with the TCZ-untreated patients. The laboratory findings in patients with full-blown MAS while treated with TCZ seemed to be similarly severe compared with the untreated patients. However, one patient with full-blown MAS while treated with TCZ was afebrile even in the period of full-blown MAS. Furthermore, in this study, eight out of 18 patients in the untreated patients were diagnosed with possible MAS, whereas 10 out of 12 patients with MAS while treated with TCZ were diagnosed with possible MAS. For patients with possible MAS treated with TCZ, only 20% were classified as having MAS, lower than the untreated patients (75%). These findings indicate that TCZ could modify clinical manifestations and key laboratory findings of MAS; thus, these differences limit the applicability of these criteria. When evaluating s-JIA patients while treated with TCZ, care must be taken to not underdiagnose MAS based on MAS classification criteria.</p><p id="Par28">Recent studies revealed some biomarkers including IL-18, CXCL9, neopterin and soluble tumor necrosis factor receptor type II might be useful for the prediction of the development of MAS and the diagnosis of the transition from active phase of s-JIA to MAS [<xref ref-type="bibr" rid="CR14">14</xref>&#x02013;<xref ref-type="bibr" rid="CR21">21</xref>]. Recent studies revealed that high levels of free IL-18 (that is, IL-18 not bound to IL-18 binding protein) increases the risk of developing MAS [<xref ref-type="bibr" rid="CR15">15</xref>, <xref ref-type="bibr" rid="CR22">22</xref>]. We previously reported that serum IL-18 levels were markedly elevated in patients with MAS while treated with TCZ and their levels positively correlated with the measures of disease activity [<xref ref-type="bibr" rid="CR3">3</xref>]. Further larger studies are desired to develop the new criteria for the diagnosis of MAS while treated with TCZ using other parameters, including IL-18, whose serum levels are not modified by TCZ.</p><p id="Par29">This study has some limitations. First, this study had a small sample size and was a retrospective analysis of a multicenter gathered cohort. Second, it was limited by the use of physician diagnosis to MAS because of an absence of gold standard for the diagnosis of MAS. Third, the suspicion for MAS might be higher in patients treated with TCZ compared to those not treated with TCZ, because the diagnosis of s-JIA were established in patients treated with TCZ. Further larger prospective studies might add value to this study.</p></sec><sec id="Sec8"><title>Conclusions</title><p id="Par30">In conclusion, TCZ could modify clinical and laboratory features of MAS. When evaluating s-JIA patients while receiving TCZ, it is not applicable to use 2016&#x02009;s-JIA associated MAS criteria for these group of patients. Care must be taken to not underdiagnose MAS based on the MAS classification criteria.</p></sec></body><back><glossary><title>Abbreviations</title><def-list><def-item><term>AST</term><def><p id="Par5">Aspartic aminotransferase</p></def></def-item><def-item><term>CRP</term><def><p id="Par6">C reactive protein</p></def></def-item><def-item><term>IL</term><def><p id="Par7">Interleukin</p></def></def-item><def-item><term>MAS</term><def><p id="Par8">Macrophage activation syndrome</p></def></def-item><def-item><term>s-JIA</term><def><p id="Par9">Systemic juvenile idiopathic arthritis</p></def></def-item><def-item><term>TCZ</term><def><p id="Par10">Tocilizumab</p></def></def-item><def-item><term>TG</term><def><p id="Par11">Triglyceride</p></def></def-item></def-list></glossary><fn-group><fn><p><bold>Publisher&#x02019;s Note</bold></p><p>Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.</p></fn></fn-group><ack><p>We thank the children and parents participating in the study.</p></ack><notes notes-type="author-contribution"><title>Authors&#x02019; contributions</title><p>All authors were involved in the conception, design of the study, the acquisition of data, and revising it critically for important intellectual content. MS was involved in analysis, interpretation of data and drafting of the manuscript. All authors read and approved the final manuscript.</p></notes><notes notes-type="funding-information"><title>Funding</title><p>This work was supported by Research on rare and intractable diseases, Health and Labour Sciences Research Grants.</p></notes><notes notes-type="data-availability"><title>Availability of data and materials</title><p>The datasets used and/or analyzed during the current study are not publicly available for ethical reasons, as well as privacy reasons, but are available from the corresponding author on reasonable request.</p></notes><notes><title>Ethics approval and consent to participate</title><p id="Par31">This is a retrospective study, approved by the Ethics Review Board of Osaka Medical College [No.333 (1964)], the main study center, on July 2016, after which approval was obtained from each of the 13 other participating medical centers. Guardians and patients were provided information by means of an opt-out form.</p></notes><notes><title>Consent for publication</title><p id="Par32">Not applicable.</p></notes><notes notes-type="COI-statement"><title>Competing interests</title><p id="Par33">Tokyo Medical and Dental University (TMDU) received unrestricted research grants for Department of Lifetime Clinical Immunology from AbbVie GK, Ayumi Pharmaceutical, Chugai Pharmaceutical, CSL Behring, Japan Blood Products Organization, Mitsubishi Tanabe Pharma, Nippon Kayaku, Ono Pharmaceutical, Towa Pharmaceutical, and UCB Japan. TMDU paid the salary of Masaaki Mori. The authors declare that they have no competing interests.</p></notes><ref-list id="Bib1"><title>References</title><ref id="CR1"><label>1.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Mellins</surname><given-names>ED</given-names></name><name><surname>Macaubas</surname><given-names>C</given-names></name><name><surname>Grom</surname><given-names>AA</given-names></name></person-group><article-title>Pathogenesis of systemic juvenile idiopathic arthritis: some answers, more questions</article-title><source>Nat Rev Rheumatol</source><year>2011</year><volume>7</volume><fpage>416</fpage><lpage>426</lpage><pub-id pub-id-type="doi">10.1038/nrrheum.2011.68</pub-id><pub-id pub-id-type="pmid">21647204</pub-id></element-citation></ref><ref id="CR2"><label>2.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Behrens</surname><given-names>EM</given-names></name><name><surname>Beukelman</surname><given-names>T</given-names></name><name><surname>Paessler</surname><given-names>M</given-names></name><name><surname>Cron</surname><given-names>RQ</given-names></name></person-group><article-title>Occult macrophage activation syndrome in patients with systemic juvenile idiopathic arthritis</article-title><source>J Rheumatol</source><year>2007</year><volume>34</volume><fpage>1133</fpage><lpage>1138</lpage><pub-id pub-id-type="pmid">17343315</pub-id></element-citation></ref><ref id="CR3"><label>3.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Shimizu</surname><given-names>M</given-names></name><name><surname>Nakagishi</surname><given-names>Y</given-names></name><name><surname>Kasai</surname><given-names>K</given-names></name><name><surname>Yamasaki</surname><given-names>Y</given-names></name><name><surname>Miyoshi</surname><given-names>M</given-names></name><name><surname>Takei</surname><given-names>S</given-names></name><etal/></person-group><article-title>Tocilizumab masks the clinical symptoms of systemic juvenile idiopathic arthritis-associated macrophage activation syndrome: the diagnostic significance of interleukin-18 and interleukin-6</article-title><source>Cytokine</source><year>2012</year><volume>58</volume><fpage>287</fpage><lpage>294</lpage><pub-id pub-id-type="doi">10.1016/j.cyto.2012.02.006</pub-id><pub-id pub-id-type="pmid">22398373</pub-id></element-citation></ref><ref id="CR4"><label>4.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Schulert</surname><given-names>GS</given-names></name><name><surname>Minoia</surname><given-names>F</given-names></name><name><surname>Bohnsack</surname><given-names>J</given-names></name><name><surname>Cron</surname><given-names>RQ</given-names></name><name><surname>Hashad</surname><given-names>S</given-names></name><name><surname>Kon&#x000c9;-Paut</surname><given-names>I</given-names></name><etal/></person-group><article-title>Effect of Biologic Therapy on Clinical and Laboratory Features of Macrophage Activation Syndrome Associated With Systemic Juvenile Idiopathic Arthritis</article-title><source>Arthritis Care Res (Hoboken)</source><year>2018</year><volume>70</volume><fpage>409</fpage><lpage>419</lpage><pub-id pub-id-type="doi">10.1002/acr.23277</pub-id><pub-id pub-id-type="pmid">28499329</pub-id></element-citation></ref><ref id="CR5"><label>5.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ravelli</surname><given-names>A</given-names></name><name><surname>Minoia</surname><given-names>F</given-names></name><name><surname>Dav</surname><given-names>S</given-names></name><name><surname>Horne</surname><given-names>A</given-names></name><name><surname>Bovis</surname><given-names>F</given-names></name><name><surname>Pistorio</surname><given-names>A</given-names></name><etal/></person-group><article-title>2016 classification criteria for macrophage activation syndrome complicating systemic juvenile idiopathic arthritis: a European league against rheumatism/American College of Rheumatology/Paediatric rheumatology international trials organisation collaborative initiative</article-title><source>Arthritis Rheumatol</source><year>2016</year><volume>68</volume><fpage>566</fpage><lpage>576</lpage><pub-id pub-id-type="doi">10.1002/art.39332</pub-id><pub-id pub-id-type="pmid">26314788</pub-id></element-citation></ref><ref id="CR6"><label>6.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Shimizu</surname><given-names>M</given-names></name><name><surname>Mizuta</surname><given-names>M</given-names></name><name><surname>Yasumi</surname><given-names>T</given-names></name><name><surname>Iwata</surname><given-names>N</given-names></name><name><surname>Okura</surname><given-names>Y</given-names></name><name><surname>Kinjo</surname><given-names>N</given-names></name><etal/></person-group><article-title>Validation of classification criteria of macrophage activation syndrome in Japanese patients with systemic juvenile idiopathic arthritis</article-title><source>Arthritis Care Res (Hoboken)</source><year>2018</year><volume>70</volume><fpage>1412</fpage><lpage>1415</lpage><pub-id pub-id-type="doi">10.1002/acr.23482</pub-id><pub-id pub-id-type="pmid">29195002</pub-id></element-citation></ref><ref id="CR7"><label>7.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>De Benedetti</surname><given-names>F</given-names></name><name><surname>Brunner</surname><given-names>HI</given-names></name><name><surname>Ruperto</surname><given-names>N</given-names></name><name><surname>Kenwright</surname><given-names>A</given-names></name><name><surname>Wright</surname><given-names>S</given-names></name><name><surname>Calvo</surname><given-names>I</given-names></name><etal/></person-group><article-title>Randomized trial of tocilizumab in systemic juvenile idiopathic arthritis</article-title><source>N Engl J Med</source><year>2012</year><volume>367</volume><fpage>2385</fpage><lpage>2395</lpage><pub-id pub-id-type="doi">10.1056/NEJMoa1112802</pub-id><pub-id pub-id-type="pmid">23252525</pub-id></element-citation></ref><ref id="CR8"><label>8.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Yokota</surname><given-names>S</given-names></name><name><surname>Itoh</surname><given-names>Y</given-names></name><name><surname>Morio</surname><given-names>T</given-names></name><name><surname>Sumitomo</surname><given-names>N</given-names></name><name><surname>Daimaru</surname><given-names>K</given-names></name><name><surname>Minota</surname><given-names>S</given-names></name></person-group><article-title>Macrophage activation syndrome in patients with systemic juvenile idiopathic arthritis under treatment with tocilizumab</article-title><source>J Rheumatol</source><year>2015</year><volume>42</volume><fpage>712</fpage><lpage>722</lpage><pub-id pub-id-type="doi">10.3899/jrheum.140288</pub-id><pub-id pub-id-type="pmid">25684767</pub-id></element-citation></ref><ref id="CR9"><label>9.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ravelli</surname><given-names>A</given-names></name><name><surname>Magni-Manzoni</surname><given-names>S</given-names></name><name><surname>Pistorio</surname><given-names>A</given-names></name><name><surname>Besana</surname><given-names>C</given-names></name><name><surname>Foti</surname><given-names>T</given-names></name><name><surname>Ruperto</surname><given-names>N</given-names></name><etal/></person-group><article-title>Preliminary diagnostic guidelines for macrophage activation syndrome complicating systemic juvenile idiopathic arthritis</article-title><source>J Pediatr</source><year>2005</year><volume>146</volume><fpage>598</fpage><lpage>604</lpage><pub-id pub-id-type="doi">10.1016/j.jpeds.2004.12.016</pub-id><pub-id pub-id-type="pmid">15870661</pub-id></element-citation></ref><ref id="CR10"><label>10.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>de Benedetti</surname><given-names>F</given-names></name><name><surname>Massa</surname><given-names>M</given-names></name><name><surname>Robbioni</surname><given-names>P</given-names></name><name><surname>Ravelli</surname><given-names>A</given-names></name><name><surname>Burgio</surname><given-names>GR</given-names></name><name><surname>Martini</surname><given-names>A</given-names></name></person-group><article-title>Correlation of interleukin-6 levels with joint involvement and thrombocytosis in patients with systemic juvenile rheumatoid arthritis</article-title><source>Arthritis Rheum</source><year>1991</year><volume>34</volume><fpage>1158</fpage><lpage>1163</lpage><pub-id pub-id-type="doi">10.1002/art.1780340912</pub-id><pub-id pub-id-type="pmid">1930333</pub-id></element-citation></ref><ref id="CR11"><label>11.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Yokota</surname><given-names>S</given-names></name><name><surname>Imagawa</surname><given-names>T</given-names></name><name><surname>Mori</surname><given-names>M</given-names></name><name><surname>Miyamae</surname><given-names>T</given-names></name><name><surname>Aihara</surname><given-names>Y</given-names></name><name><surname>Takei</surname><given-names>S</given-names></name><etal/></person-group><article-title>Efficacy and safety of tocilizumab in patients with systemic-onset juvenile idiopathic arthritis: a randomised, double-blind, placebo-controlled, withdrawal phase III trial</article-title><source>Lancet</source><year>2008</year><volume>371</volume><fpage>998</fpage><lpage>1006</lpage><pub-id pub-id-type="doi">10.1016/S0140-6736(08)60454-7</pub-id><pub-id pub-id-type="pmid">18358927</pub-id></element-citation></ref><ref id="CR12"><label>12.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Yokota</surname><given-names>S</given-names></name><name><surname>Itoh</surname><given-names>Y</given-names></name><name><surname>Morio</surname><given-names>T</given-names></name><name><surname>Origasa</surname><given-names>H</given-names></name><name><surname>Sumitomo</surname><given-names>N</given-names></name><name><surname>Tomobe</surname><given-names>M</given-names></name><etal/></person-group><article-title>Tocilizumab in systemic juvenile idiopathic arthritis in a real-world clinical setting: results from 1 year of postmarketing surveillance follow-up of 417 patients in Japan</article-title><source>Ann Rheum Dis</source><year>2016</year><volume>75</volume><fpage>1654</fpage><lpage>1660</lpage><pub-id pub-id-type="doi">10.1136/annrheumdis-2015-207818</pub-id><pub-id pub-id-type="pmid">26644233</pub-id></element-citation></ref><ref id="CR13"><label>13.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kessler</surname><given-names>EA</given-names></name><name><surname>Vora</surname><given-names>SS</given-names></name><name><surname>Verbsky</surname><given-names>JW</given-names></name></person-group><article-title>Risk of significant cytopenias after treatment with tocilizumab in systemic juvenile arthritis patients with a history of macrophage activation syndrome</article-title><source>Pediatr Rheumatol Online J</source><year>2012</year><volume>10</volume><fpage>30</fpage><pub-id pub-id-type="doi">10.1186/1546-0096-10-30</pub-id><pub-id pub-id-type="pmid">22931129</pub-id></element-citation></ref><ref id="CR14"><label>14.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Shimizu</surname><given-names>M</given-names></name><name><surname>Yokoyama</surname><given-names>T</given-names></name><name><surname>Yamada</surname><given-names>K</given-names></name><name><surname>Kaneda</surname><given-names>H</given-names></name><name><surname>Wada</surname><given-names>H</given-names></name><name><surname>Wada</surname><given-names>T</given-names></name><name><surname>Toma</surname><given-names>T</given-names></name><name><surname>Ohta</surname><given-names>K</given-names></name><name><surname>Kasahara</surname><given-names>Y</given-names></name><name><surname>Yachie</surname><given-names>A</given-names></name></person-group><article-title>Distinct cytokine profiles of systemic-onset juvenile idiopathic arthritis-associated macrophage activation syndrome with particular emphasis on the role of interleukin-18 in its pathogenesis</article-title><source>Rheumatol (Oxford)</source><year>2010</year><volume>49</volume><fpage>1645</fpage><lpage>1653</lpage><pub-id pub-id-type="doi">10.1093/rheumatology/keq133</pub-id></element-citation></ref><ref id="CR15"><label>15.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Shimizu</surname><given-names>M</given-names></name><name><surname>Nakagishi</surname><given-names>Y</given-names></name><name><surname>Inoue</surname><given-names>N</given-names></name><name><surname>Mizuta</surname><given-names>M</given-names></name><name><surname>Ko</surname><given-names>G</given-names></name><name><surname>Saikawa</surname><given-names>Y</given-names></name><name><surname>Kubota</surname><given-names>T</given-names></name><name><surname>Yamasaki</surname><given-names>Y</given-names></name><name><surname>Takei</surname><given-names>S</given-names></name><name><surname>Yachie</surname><given-names>A</given-names></name></person-group><article-title>Interleukin-18 for predicting the development of macrophage activation syndrome in systemic juvenile idiopathic arthritis</article-title><source>Clin Immunol</source><year>2015</year><volume>160</volume><fpage>277</fpage><lpage>281</lpage><pub-id pub-id-type="doi">10.1016/j.clim.2015.06.005</pub-id><pub-id pub-id-type="pmid">26101092</pub-id></element-citation></ref><ref id="CR16"><label>16.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Weiss</surname><given-names>ES</given-names></name><name><surname>Girard-Guyonvarc'h</surname><given-names>C</given-names></name><name><surname>Holzinger</surname><given-names>D</given-names></name><name><surname>de Jesus</surname><given-names>AA</given-names></name><name><surname>Tariq</surname><given-names>Z</given-names></name><name><surname>Picarsic</surname><given-names>J</given-names></name><etal/></person-group><article-title>Interleukin-18 diagnostically distinguishes and pathogenically promotes human and murine macrophage activation syndrome</article-title><source>Blood</source><year>2018</year><volume>131</volume><fpage>1442</fpage><lpage>1455</lpage><pub-id pub-id-type="doi">10.1182/blood-2017-12-820852</pub-id><pub-id pub-id-type="pmid">29326099</pub-id></element-citation></ref><ref id="CR17"><label>17.</label><mixed-citation publication-type="other">Yasin S, Fall N, Brown RA, Henderlight M, Canna SW, Girard-Guyonvarc'h C, Gabay C, Grom AA, Schulert GS. IL-18 as a biomarker linking systemic juvenile idiopathic arthritis and macrophage activation syndrome. Rheumatol (Oxford). 2019; in press.</mixed-citation></ref><ref id="CR18"><label>18.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bracaglia</surname><given-names>C</given-names></name><name><surname>de Graaf</surname><given-names>K</given-names></name><name><surname>Pires Marafon</surname><given-names>D</given-names></name><name><surname>Guilhot</surname><given-names>F</given-names></name><name><surname>Ferlin</surname><given-names>W</given-names></name><name><surname>Prencipe</surname><given-names>G</given-names></name><name><surname>Caiello</surname><given-names>I</given-names></name><name><surname>Dav&#x000ec;</surname><given-names>S</given-names></name><name><surname>Schulert</surname><given-names>G</given-names></name><name><surname>Ravelli</surname><given-names>A</given-names></name><name><surname>Grom</surname><given-names>AA</given-names></name><name><surname>de Min</surname><given-names>C</given-names></name><name><surname>De Benedetti</surname><given-names>F</given-names></name></person-group><article-title>Elevated circulating levels of interferon-&#x003b3; and interferon-&#x003b3;-induced chemokines characterise patients with macrophage activation syndrome complicating systemic juvenile idiopathic arthritis</article-title><source>Ann Rheum Dis</source><year>2017</year><volume>76</volume><fpage>166</fpage><lpage>172</lpage><pub-id pub-id-type="doi">10.1136/annrheumdis-2015-209020</pub-id><pub-id pub-id-type="pmid">27296321</pub-id></element-citation></ref><ref id="CR19"><label>19.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Mizuta</surname><given-names>M</given-names></name><name><surname>Shimizu</surname><given-names>M</given-names></name><name><surname>Inoue</surname><given-names>N</given-names></name><name><surname>Nakagishi</surname><given-names>Y</given-names></name><name><surname>Yachie</surname><given-names>A</given-names></name></person-group><article-title>Clinical significance of serum CXCL9 levels as a biomarker for systemic juvenile idiopathic arthritis associated macrophage activation syndrome</article-title><source>Cytokine</source><year>2019</year><volume>119</volume><fpage>182</fpage><lpage>187</lpage><pub-id pub-id-type="doi">10.1016/j.cyto.2019.03.018</pub-id><pub-id pub-id-type="pmid">30952065</pub-id></element-citation></ref><ref id="CR20"><label>20.</label><mixed-citation publication-type="other">Takakura M, Shimizu M, Irabu H, Sakumura N, Inoue N, Mizuta M, Nakagishi Y, Yachie A. Comparison of serum biomarkers for the diagnosis of macrophage activation syndrome complicating systemic juvenile idiopathic arthritis. Clin Immunol. 2019; in press.</mixed-citation></ref><ref id="CR21"><label>21.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Shimizu</surname><given-names>M</given-names></name><name><surname>Inoue</surname><given-names>N</given-names></name><name><surname>Mizuta</surname><given-names>M</given-names></name><name><surname>Nakagishi</surname><given-names>Y</given-names></name><name><surname>Yachie</surname><given-names>A</given-names></name></person-group><article-title>Characteristic elevation of soluble TNF receptor II : I ratio in macrophage activation syndrome with systemic juvenile idiopathic arthritis</article-title><source>Clin Exp Immunol</source><year>2018</year><volume>191</volume><fpage>349</fpage><lpage>355</lpage><pub-id pub-id-type="doi">10.1111/cei.13026</pub-id><pub-id pub-id-type="pmid">28815559</pub-id></element-citation></ref><ref id="CR22"><label>22.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Girard-Guyonvarc'h</surname><given-names>C</given-names></name><name><surname>Palomo</surname><given-names>J</given-names></name><name><surname>Martin</surname><given-names>P</given-names></name><name><surname>Rodriguez</surname><given-names>E</given-names></name><name><surname>Troccaz</surname><given-names>S</given-names></name><name><surname>Palmer</surname><given-names>G</given-names></name><name><surname>Gabay</surname><given-names>C</given-names></name></person-group><article-title>Unopposed IL-18 signaling leads to severe TLR9-induced macrophage activation syndrome in mice</article-title><source>Blood</source><year>2018</year><volume>131</volume><fpage>1430</fpage><lpage>1441</lpage><pub-id pub-id-type="doi">10.1182/blood-2017-06-789552</pub-id><pub-id pub-id-type="pmid">29295842</pub-id></element-citation></ref></ref-list></back></article>